구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ustekinumab (Stelara, 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab) Janssen·Ulcerative Colitis (UC) 1 trials |
|---|---|
Overview Program | 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab |
Overview Company | Janssen |
Overview Modality | ANTIBODY |
Overview Target | Ulcerative Colitis (UC) |
Overview Indication | Ulcerative Colitis (UC) |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Toxicology Major finding | Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.. There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with moderate-to-severe… |
Clinical Safety signal | Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.. There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with moderate-to-severe… |
Clinical Program phase | APPROVED |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ustekinumab (Stelara, 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab) Janssen·Ulcerative Colitis (UC) 1 trials |
|---|---|
Overview Program | 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab |
Overview Company | Janssen |
Overview Modality | ANTIBODY |
Overview Target | Ulcerative Colitis (UC) |
Overview Indication | Ulcerative Colitis (UC) |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Toxicology Major finding | Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.. There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with moderate-to-severe… |
Clinical Safety signal | Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.. There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with moderate-to-severe… |
Clinical Program phase | APPROVED |
추천 비교
추천 비교